Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.
Globus Medical (GMED) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.
Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises
by Zacks Equity Research
Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.
Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.
DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.
Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook
by Zacks Equity Research
Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.
Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended
by Zacks Equity Research
Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls
by Zacks Equity Research
Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.
NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.
QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.
AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.
Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.
Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.
Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify
by Zacks Equity Research
Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify
Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.
Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate
by Zacks Equity Research
Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.